A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma

Lignende værker

• A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma
  af: Yukari Bando, et al.
  Udgivet: (2019-12-01)
• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  af: Raedler, Lisa A.
  Udgivet: (2015)
• Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
  af: Tang, Xiao-Yi, et al.
  Udgivet: (2016)
• Multicentre, open-label, randomised controlled clinical trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild-to-moderate stenotic lesions with high-risk plaques in coronary arteries: study protocol
  af: Matsuda, Morihiro, et al.
  Udgivet: (2019)
• Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
  af: Paoluzzi, L., et al.
  Udgivet: (2016)